Reshape Lifesciences Inc. (24O0)
XMUN 
NASDAQ (CM) Primary XMUN Summary
24O0 Chart
ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Earnings Highlights and Strategic Business Update Conference April 10, 2025 4:30 PM ET Company Participants Michael Miller - IR, Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Operator Good afternoon, and thank you for joining the ReShape Lifesciences Earnings Highlights and Strategic Update Conference Call. I would now like to turn the call over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call.
Reshape Lifesciences Inc. (24O0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Reshape Lifesciences Inc. ever had a stock split?
Reshape Lifesciences Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Paul F. Hickey CEO | XMUN Exchange | US92943X1046 ISIN |
| US Country | 17 Employees | - Last Dividend | 15 Aug 2025 Last Split | 15 Nov 2007 IPO Date |
Overview
ReShape Lifesciences Inc. is a pioneering medical device company dedicated to managing and treating obesity and metabolic diseases. Operating across the United States, Australia, Europe, and on an international scale, the company has a robust product portfolio aimed at providing minimally invasive to non-invasive solutions for severe obesity management and the treatment of metabolic diseases. Initially known as EnteroMedics Inc., the company rebranded to ReShape Lifesciences Inc. in 2017, building on its commitment to innovation in the field of weight management. Founded in 2002 and headquartered in San Clemente, California, ReShape Lifesciences Inc. continues to lead the way in developing technologies that offer sustainable, healthy lifestyle adjustments for patients around the globe.
Products and Services
Lap-Band System: A cornerstone of the company's product line, the Lap-Band System provides a minimally invasive treatment option for severe obesity. This long-term solution is an alternative to more invasive procedures like gastric bypass or sleeve gastrectomy, focusing on reducing stomach size to control food intake.
ReShape Vest System: An innovative laparoscopically implantable device designed to promote weight loss while preserving the stomach's integrity. This system represents a significant advancement in obesity management technology, providing patients with a tool to achieve and maintain significant weight loss without undergoing extensive surgery.
ReShapeCare Virtual Health Coaching Program: Understanding that weight loss and healthy living are multifaceted challenges, ReShape Lifesciences offers a comprehensive virtual health coaching program. ReShapeCare supports patients undergoing medically managed weight-loss treatment by promoting sustainable lifestyle changes, ensuring support and guidance every step of the way.
ReShape Diabetes Bloc-Stim Neuromodulation: Currently in preclinical development, this cutting-edge technology aims to treat type 2 diabetes mellitus through neuromodulation. It showcases ReShape Lifesciences' commitment to tackling metabolic diseases with innovative approaches that extend beyond traditional treatments.
Obalon Balloon System: A less invasive option for weight loss, the Obalon Balloon System involves a swallowable capsule that inflates into a balloon inside the stomach. This device is designed to help control portion size and is accompanied by a tracking system to monitor the balloon's placement, ensuring safety and effectiveness throughout its use.
